Netoglitazone

A less potent IWP-2 derivative that has been used to determine which structural features of IWP-2 are essential for impairing Wnt/ &beta-catenin pathway activity.

A potent inhibitor of the Wnt response, blocking a cell-based Wnt/&beta-catenin pathway reporter response (IC₅₀= 180 nM) inhibits Wnt-induced accumulation of &beta-catenin, leading to proteasomal degradation of this protein.

A potent inhibitor of the Wnt response, blocking a cell-based Wnt/&beta-catenin pathway reporter response (IC₅₀= 180 nM) inhibits Wnt-induced accumulation of &beta-catenin, leading to proteasomal degradation of this protein.

A potent inhibitor of the Wnt response, blocking a cell-based Wnt/&beta-catenin pathway reporter response (IC₅₀= 180 nM) inhibits Wnt-induced accumulation of &beta-catenin, leading to proteasomal degradation of this protein.

JNJ-46281222 is an metabotropic glutamate (mGlu) 2 -selective, highly potent PAM (positive allosteric modulator) with nanomolar affinity ( K d = 1.7 nM) and a high modulatory potency ( pEC 50 = 7.71)In VitroJNJ‐4628122 binds to the selected

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC 50 s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.In VitroJNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC 50 s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.In VitroJNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7

A potent, reversible inhibitor of the p38&alpha isoform of MAP kinase (IC₅₀ = 32 nM) that does not inhibit the p38&gamma isoform.

InformationKY19382 (A3051) is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β with IC50 of 19 nM and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI